Here we performed longitudinal systems-level analyses in 23 trans men and found that testosterone modulates a cross-regulated axis between type-I interferon and tumour necrosis factor. Females respond more strongly to vaccines, and adverse reactions are more frequent3, like most autoimmune diseases4. Infectious, inflammatory and autoimmune conditions present differently in males and females. Regular communication, steady follow-up, and a shared plan of care make TRT a therapy that you can maintain with confidence over time. Understanding your lab results, knowing what symptoms to watch for, and taking action early all help keep your health on track.
To investigate the relative contribution of increased testosterone and suppressed oestradiol on immune cell responses, we collected blood from 11 cisgender female participants of reproductive age and pretreated blood samples with testosterone, with and without the AR inhibitor enzalutamide as a control. We verified pDC classification without pre-DC inclusion (Extended Data Fig. 3a)10 and found interferon-stimulated genes (ISGs), ISG20, PAPR14, SP110 and MX1 (counts) to be less induced after 3 months of testosterone as compared with baseline (Fig. 2g). Hallmark IFNα responses decrease after 12 months of testosterone treatment, TNF signalling through NFκB and Hallmark inflammatory responses increased after 12 months of testosterone treatment as compared with baseline. By analysing plasma proteins, immune cell phenotypes and functional immune cell responses in vitro, we searched for coordinated changes among cell populations and the protein mediators by which these communicate to understand global changes in response to testosterone treatment. TRT often increases hemoglobin because testosterone stimulates red blood cell production (erythropoiesis). Sometimes, a person may have a condition called polycythemia vera (PV), a rare disorder in which the bone marrow makes too many red blood cells.
For a CBC blood test, a healthcare provider takes a sample of your blood and sends it to a lab. A provider can use it to monitor and diagnose medical conditions and check on the health of your immune system. Get baseline bloodwork before starting any research, monitor during protocols, and track recovery afterward.
The cut-off thresholds for each sample were chosen on the basis of distribution shape of read counts to retain biologically relevant cells and to eliminate technical artifacts. Viability and cell counts were assessed after resuspending collected cells in PBS with 0.04% BSA (ThermoFisher Scientific). Cryopreserved PBMCs obtained at baseline and after 3 months of testosterone treatment were thawed in thawing medium (RPMI 1640 HyClone supplemented with 10% FBS, 1% penicillin-streptomycin and Benzonase-nuclease (Sigma-Aldrich)). Intracellular IFNγ was measured by mass cytometry and we found that pretreatment with DHT, but not loss of ESR signalling (fulvestrant), potentiated IFNγ responses by CD56dim NK cells, but not T cells (Fig. 4g and Extended Data Fig. 5i). Collectively, these findings support the view that NK cell function is potentiated during GAHT as a consequence of induced IL-12 responses by monocytes following testosterone treatment (Fig. 4f). All target genes (top half of circle) are upregulated after testosterone treatment in vivo in NK cells and CD8+ T cells. Sex differences in CD4+ T cell polarization have been reported27, but in our sc-mRNA-seq data, no difference in TH1, TH2 or TH17 marker genes occurred during testosterone therapy (Extended Data Fig. 5e–g).
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some people with PV may also need cytoreductive therapy. Tobacco and carbon monoxide raise red cell levels The high hemoglobin or hematocrit does not usually cause symptoms on its own. Some therapies or hormonal conditions can raise hemoglobin and hematocrit.
These forms of TRT deliver testosterone through the skin. While SubQ injections can still raise hemoglobin, they tend to do so less aggressively. Some clinicians report that patients switching from IM to SubQ injections see a decrease in hemoglobin over time. Research has found that IM injections lead to the highest rate of erythrocytosis (high hematocrit) among all TRT options. They are usually given every 1 to 2 weeks, depending on the type of testosterone prescribed. One major factor that changes how your body reacts is the type of TRT you use and the dose you receive. Testosterone replacement therapy (TRT) affects each person differently.

Gender: Female

Social links